Ruxolitinib Hydrochloride is a selective Janus kinase (JAK) inhibitor, specifically targeting JAK1 and JAK2, widely utilized in the clinical management of myelofibrosis, polycythemia vera, and graft-versus-host… Read more
Ruxolitinib Hydrochloride is a selective Janus kinase (JAK) inhibitor, specifically targeting JAK1 and JAK2, widely utilized in the clinical management of myelofibrosis, polycythemia vera, and graft-versus-host disease. Pharmaceutical laboratories rely on accurate characterization of this active pharmaceutical ingredient to ensure product safety and regulatory compliance. This category includes comprehensive reference standards, such as structurally characterized impurities and metabolic degradation products, which are essential for rigorous impurity profiling during manufacturing. Additionally, stable isotope labelled compounds are available to serve as critical internal standards for high-resolution mass spectrometry and quantitative quality control. By utilizing these specialized reference materials, analytical teams can successfully perform method validation, forced degradation studies, and stability testing, ensuring the continued quality and consistency of the pharmaceutical product throughout its entire development and production lifecycle.